IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A REVIEW ARTICLE ON GESTATIONAL DIABETES MELLITUS

Suryawanshi Shweta Dadaji*, Mairal Pooja Balkrushna, Wani Gitanjali Suryakant[1], Suryawanshi Vaishnavi Rajendra[2], Shinde Kavita Raghunath[3]**

Author: B.Pharm Student*, Co-Auther: B.Pharm Student[1,2,3] & Guide Assistant Professor(M.Pharm, Dept. Pharmaceutical Chemistry)

Swami Vivekananda Sansth's Institute Of Pharmcy(B.Pharm.), Mungase, Tal. Malegon, Dist. Nashik-423201

ABSTRACT

Diabetes mellitus is a chronic condition that necessitates constant medical attention as well as patient education and assistance for self-management in order to avoid acute problems and lessen long-term effects. The most frequent medical problem associated with pregnancy is gestational diabetes mellitus (GDM). Pregnancy-associated moderate to severe maternal hyperglycemia poses particular dangers for the mother and her unborn child related to diabetes. Gestational diabetes mellitus (GDM) is therefore a carbohydrate intolerance that has developed or been identified for the first time during pregnancy but is not diabetes. The prevalence of GDM is 7% of pregnancies. Patients with GDM are more likely to experience preeclampsia, abnormal weight gain, and caesarean sections. Children born to moms who have GDM are more likely to experience macrosomia, birth injuries, and shoulder dystocia. These newborns are more likely to experience respiratory distress, hyperbilirubinemia, hypoglycemia, and hypocalcemia after birth. GDM is linked to both hypertensive diseases during pregnancy and to immediate pregnancy issues such excessive foetal development and obesity. However, the links between a variety of longer-term maternal and foetal health outcomes, such as lifelong risks for obesity, pre-diabetes, diabetes, and cardiovascular disease, have gotten less attention, and few health systems systematically address these crucial issues. This article examines historical and contemporary data on the use of demographic, clinical, and biochemical indicators to predict the development of GDM. We assess existing and prospective new diagnostic methods intended to most accurately detect GDM, and we further this study into a critical assessment of lifestyle, dietary, and pharmaceutical factors.

KEYWORDS: gestational diabetes, classification, prediction diagnosis, risk factor, pathophysiology, medical nutritional therapy, oral hypoglycemic agents

INTRODUCTION

Diabetes mellitus is a chronic condition that necessitates constant medical attention as well as patient education and assistance for self-management in order to avoid acute problems and lessen long-term effects. Due to the complexity of diabetes care, approaches for multidimensional risk reduction are also required in addition to glucose control. There is a substantial body of research supporting a variety of therapies to enhance diabetes outcomes. [1]

Moderate to severe maternal hyperglycemia during pregnancy carries special diabetes-related hazards because it may have long-term effects on both the mother and her unborn child. To distinguish it from type 1 or type 2 diabetes that has already been diagnosed or maturity-onset diabetes of the young (MODY) in pregnant women, gestational diabetes (GDM) has been described as any degree of glucose intolerance that begins or is first noticed during pregnancy. Hence, under this wide definition of GDM, women whose glucose intolerance develops during pregnancy as well as those who have undiagnosed pre-existing diabetes are included. The distinction is crucial because, unlike the majority of foetuses whose mothers experience glucose intolerance during pregnancy, those whose mothers have pre-existing diabetes may be exposed to hyperglycemia in the first two trimesters of pregnancy, increasing their risk of a variety of single and multiple cardiovascular and other abnormalities (including central nervous system and musculoskeletal defects). The International Association of Diabetes and Pregnancy Study Groups (IADPSG) consensus panel recently advised that highrisk women who are confirmed to have diabetes at their first prenatal appointment be classified with over diabetes rather than gestational diabetes mellitus (GDM). [2]

Type 2 diabetes, whose incidence is quickly rising around the world, is mostly brought on by genetic causes, along with acquired variables including stress, ageing, lack of exercise, obesity brought on by a high-fat diet, and lack of sleep. There is a definite trend in Japan towards delaying marriage and childbearing, and it is anticipated that more and more pregnant women with decreased glucose tolerance may experience gestational diabetes mellitus in the future. It is a known fact that pregnant women age 35 and older have a roughly 8 times higher incidence of GDM than pregnant women age 25 or younger.

The prevalence of GDM is 7% of pregnancies. There may be a substantially higher prevalence and greater propensity for diabetes in certain minority populations. Patients with GDM are more likely to experience preeclampsia, abnormal weight gain, and caesarean sections. Children born to moms who have GDM are more likely to experience macrosomia, birth injuries, and shoulder dystocia. Upon delivery, these newborns are more

likely to experience respiratory distress syndrome, polycythemia, hyperbilirubinemia, hypoglycemia, and hypocalcemia, which can lead to obesity and type 2 diabetes later in life. [3]

DEFINATION

Gestational diabetes mellitus (GDM) is defined as any degree of hyperglycaemia that is recognized for the first time during pregnancy. [4]

Macrosomia, the tendency for pregnant women with gestational diabetes to have large babies, can complicate labour and delivery. Prematurely low blood sugar levels are also more likely to occur in newborns whose moms with gestational diabetes. These people are more vulnerable to type 2 diabetes, heart disease, and obesity later in life.

CLASSIFICATION OF DIABETES IN PREGNANCY

It is essential to categorise the anomalies of glucose intolerance that are observed during pregnancy for epidemiological and clinical reasons. Gestational diabetes mellitus (GDM), according to earlier studies from the World Health Organization (WHO), is either diabetes or glucose intolerance that is primarily discovered during pregnancy. There is insufficient good evidence from randomised controlled clinical studies to support this broad definition of GDM, which includes a category of "severe hyperglycaemia" (RCTs) . [5]

Several studies looked into the relationship between a mother's glycaemic status and the outcome for both the mother and the foetus. Nevertheless, the design of these trials did not take "severe hyperglycaemia" into account. For instance, moms who had fasting blood glucose levels greater than 5.8 mmol/L and 2-h post oral glucose loads greater than 11.1 mmol/L were disqualified from the HAPO research. [6]

Mothers with fasting blood glucose levels below 7.0 mmol/L and 2-h post oral glucose loads above 11.0 mmol/L were excluded from the Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS)[6]. Mothers with fasting blood glucose levels below 5.3 mmol/L were also disqualified from the experiment in a research by Landon The International Association of Diabetes and Pregnancy Study Groups (IADPSG) has coined the term "overt diabetes" to refer to the category of extreme hyperglycemia that mimics pre-existing diabetes (PED).[7]

Dr. Priscilla White created the original version of the traditional categorization system for gestational diabetes in 1949; this system is now known as the White's classification. Dr. White classified diabetes in pregnancy into groups from "A" (more favourable) to "F" based on the age at beginning, duration of the diabetes, metabolic problems, and vascular issues (less favourable). Several changes were made to the original White's classification before 1980. [8]

The first amendment was made in 1965 and included class "R" to indicate the existence of proliferative retinopathy while moving vascular problems to class "D." At a later revision made in 1972, class "D" was broken into five categories and GDM was added to class "A." White's categorization has recently undergone some changes, including the addition of GDM as a distinct new class and the deletion of classes "E" and "G." [8]

The American College of Obstetricians and Gynecologists (ACOG) questioned the validity of the White's classification in clinical practise and advocated a different classification for GDM, including a note for the presence or absence of metabolic problems. [9]

The phrase "diabetes in pregnancy" has recently been proposed to refer to all instances of hyperglycemia noticed during pregnancy, including PED and GDM. Pre-gestational type 2 diabetes mellitus (T2DM) and type 1 diabetes mellitus are among the latter (T1DM) [10]

GDM is characterised as any level of hyperglycemia that is identified for the first time while a woman is pregnant. This definition of GDM should be considered to encompass both cases of real GDM that emerge later in pregnancy and cases of undiagnosed T2DM "overt diabetes" that are discovered early in pregnancy. [10, 11, 12]



Fig. Classification of Diabetes in pregnancy

GDM PREDICATION

GDM PREDICTION As was already mentioned, many women who are today labelled as having "GDM" may actually have had undiagnosed hyperglycemia prior to becoming pregnant. The optimal preconception care in high incidence nations would include hyperglycemia screening as part of well-planned and resourced preconception care. This strategy, however, has some drawbacks because only around 40% of pregnancies worldwide are "planned." We cannot categorically claim that testing during early pregnancy is "predicting" GDM due to the lack of preconception testing. Early testing does, however, offer a chance to identify some women who likely already have problems in their glucose metabolism. For instance, in India, it has been claimed that at their first antenatal appointment, more than 70% of GDM women can be recognised. [13,14]

Additionally, it may be possible to identify a distinct group of pregnant women with glucose levels that are within the normal range in the early stages of pregnancy but who have a high chance of developing "standard GDM," which is normally identified by clinical traits and biochemical tests between 24 and 28 weeks of gestation. It makes sense, practically, to concentrate early intervention efforts on women with pre-pregnancy hyperglycemia, early-stage GDM, and high-risk GDM.GD A marker for (premature) cardiovascular (CV) illness in women and an erroneous precursor to eventual Type 2 diabetes. GDM and Type 2 diabetes share a number of underlying mechanisms, including insulin resistance, chronic metabolic inflammation, changes in adipocytokines, and modifications in many areas of metabolism, in addition to their shared sine qua non of hyperglycemia. The simplest models for GDM prediction stratify GDM risk based on one or more clinical variables. Van Hoorn et al. most recently assessed the effectiveness of these models.[15,16]

Who came to the conclusion that the most accurate models for prediction were those that combined various clinical factors with early pregnancy glucose readings? Using demographic data and prior laboratory findings, machine learning or artificial intelligence techniques have recently been used to increase predictive capability. GDM is also linked to early pregnancy markers such pregnancy-associated plasma protein A (PAPP-A) and free b, which are frequently used to predict aneuploidy. Moreover, HCG are included in forecasting models Researchers in Sydney have reported that the use of numerous biochemical indicators in conjunction with clinical features can accurately predict GDM using stored serum samples from a first trimester screening programme [area under receiver operator curve (AUROC) 0.91-0.93]. These results need to be confirmed in separate cohorts, though. Early prenatal proteomic screening identified a number of possible protein indicators, including a cluster linked to insulin production, binding, resistance, and signalling for later GDM [17, 18]. According to Ravnsborg et al., vitronectin, which is linked to metabolic syndrome even when not pregnant, considerably improves the prognostic value of maternal risk variables. This could show to be a useful predictor in therapeutic applications. Proteomic technologies must first develop into automated, inexpensive laboratory tests because they are currently too difficult and expensive for routine use. [17,18]

Extracellular vesicles (ECVs) have recently been studied as GDM markers. These circulating particles, which are predominantly formed from the placenta and adipose tissue during pregnancy, "package" a variety of possible protein and RNA molecules and deliver them to particular locations. James-research Allan's has shown that certain small ECVs are linked to GDM, and that giving rodents human ECVs from GDM patients causes insulin resistance and decreased insulin production, mimicking the pathophysiology of the disease. Micro RNAs, which are essential for the metabolism of glucose, are abundant in ECVs.Micro RNA-223 and micro RNA 23a were found to be highly predictive of subsequent GDM in first trimester blood samples, according to an exploratory case-control research by Yoffe (AUROC 0.91) [19] This result for micro RNA233 has been verified by a recent cohort investigation. [20 Recently, extensive research on the relationships between non-coding RNAs and GDM has been conducted, and the findings are encouraging.. [21] The required assays will also need to be modified to allow low cost, high throughput use in routine diagnostic

laboratories.In summary, cohort studies have revealed multiple potential early pregnancy predictors of later GDM.However, as is the case for These encouraging results from small studies need to be confirmed in independent cohorts using different biomarkers.They can include one or more clinical or demographic measurements, as well as data on early pregnancy's glucose levels and a complicated network of molecular indicators. Molecular biomarkers must both outperform clinical risk factors and straightforward glucose tests in predicting GDM and pregnancy outcomes and show cost-effectiveness in order to be useful in ordinary clinical practise. Practically speaking, they ought to be suitable for non-fasting testing in addition to other early pregnancy health screening procedures. Even though several biomarkers have a good correlation with subsequent GDM, none have been adequately developed as automated and affordable assays to be used on a regular basis in clinical practise. Yet, they provide important insights into the pathophysiology of GDM and could eventually be used in clinics. [22,23]

Epidemiology

The range of the reported prevalence of GDM was 1 to 14%. It depends on the population being investigated, the screening methods, and the diagnostic standards that were applied. According to estimates, the prevalence in the US, the UK, and the countries of Europe was 5%, 3-7%, and 2-6%, respectively. GDM was shown to be more common in women of African, Asian, Indian, and Hispanic descent. Numerous demographic studies revealed that type 2 diabetes, which was once a disease of the elderly, was now increasingly afflicting women during their fertile years. These research also revealed that the rising incidence of GDM parallels that of its type 2 group. The prevalence would continue to rise along with the new diagnostic criteria, which included more individuals with less severe hyperglycemia and an increase in the prevalence of obesity. [24]

Diagnosis of GDM

An oral glucose tolerance test (OGTT) given between 24 and 28 weeks of gestation is typically used to diagnose GDM. Since the majority of the physiological insulin resistance associated with the pregnancy would be fully established, this timing has typically been recommended for routine GDM diagnosis. The high rates of GDM diagnosis in early pregnancy seen in recent research from many regions of the world suggest that this assumption may no longer be true due to increased maternal ages, global levels of obesity, and other environmental risk factors. The necessity to rule out preexisting undetected diabetes at the earliest opportunity is increased by the rising prevalence of undiagnosed dysglycaemia (diabetes and pre-diabetes) in reproductive-age women, calling into question the previous standard of testing between 24 and 28 weeks. The specific method [25]

Alternative diagnostic strategies are however permitted for China, India, South America, and the United Kingdom under the pragmatic FIGO (26] recommendations, which take into account various health care environments. In the USA and Canada, there is a significant difference in the diagnostic methodology used. These countries often choose two-step testing, employing a non-fasting 1h "glucose challenge" test (GCT)

followed by an OGTT (100 gram or 75 gram) if the GCT result rises over set criteria. Additionally endorsing the need for early testing in addition to testing within the customary 24 to the 28-week window are FIGO, WHO, and IADPSG. [27]

The ongoing argument over whether testing should be universal (for all pregnant women) or restricted to those with known risk factors that increase the likelihood of a positive test is another significant variance in testing techniques for GDM around the world. Universal testing is advised by FIGO, the IADPSG, and the American College of Obstetricians and Gynaecologists (ACOG). [28] Even after accounting for a number of other maternal factors, such as BMI, the HAPO trial amply established that OGTT glucose readings are independently related with unfavorable pregnancy outcomes. A diagnostic technique focused on symptoms is obviously unworkable because GDM is almost universally asymptomatic. According to a cost utility study conducted in the United Kingdom (UK), universal OGTT is the most cost-effective option when the population frequency of GDM is more than 4.2%. There are currently no plausible estimations of GDM frequency that are lower than this limit. However, some organisations continue to advocate for risk factor-based screening, most notably the National Institute for Clinical Excellence (NICE) in the UK. The most recent Cochrane analysis is inconclusive, although a recent systematic assessment of economic analyses of GDM screening once again came to the conclusion that universal screening was the best course of action. In nations as disparate as Sweden, where only 31% of women underwent the screening test deemed appropriate for their documented risk factor profile, and the UK (61% appropriate screening according to risk factors), compliance with officially sanctioned risk factor-based screening regimens appears to be low. And in South Africa, Adam et al. found that, despite risk factors reducing OGTTs by 46%, this technique missed diagnosing 41% of GDM cases.Another Italian study found that risk factor-based screening would miss 23% of GDM patients. In contrast, a study from Sri Lanka, a nation with a high background prevalence of diabetes, found that only 13% of GDM cases would go unreported if risk variables were utilised to assess the need for OGTT.As a result, different populations experience risk factor-based screening in different ways. However, considering that risk factor-based screening is not properly implemented and that GDM and its related risk factors are becoming more prevalent in most countries, we propose standardised biochemical testing. [29]

Clearly, an alternative inexpensive, repeatable, non-fasting test would be preferred to the glucose tolerance test because it is uncomfortable, resource consuming, and quite poorly reproducible.[30] Self-administered home OGTTs tend to work equally as well as lab tests and provide more convenience. Specific metres with stringent laboratory-based quality control may also give acceptable accuracy for fasting glucose testing, and FIGO has validated this strategy for use in limited resource settings.[31,32]

An obvious substitute and frequently used for diabetes diagnosis outside of pregnancy is glycosylated hemoglobin (HbA1c). It appears to be of minimal benefit, except from the early pregnancy identification of undiagnosed hyperglycemia, and performs poorly in both the prediction of OGTT-diagnosed GDM and the prediction of pregnancy outcomes.[33,34]

Fructosamine (FA), glycated albumin (GA), and 1.5 anhydroglucitrol (1.5 AHG) are only a few of the various indicators of overall glycemia that have been studied. These markers have shorter half-lives, making them more indicative of short-term glycemic alterations. None of these markers are best used during pregnancy. Although FA is easily tested, pregnancy-related dilutional anemia affects it. Due to a lowered renal threshold for glycosuria, FA and GAvary are incorrect in the presence of albuminuria (as in pre-eclampsia) and 1.5 AHG in pregnancy. In more recent investigations, it was discovered that the glycated complement fraction GCD59 was linked to early GDM and large for gestational age (LGA) newborns in a pregnant population with obesity. Now being conducted are larger prospective evaluations. The non-fasting marker of overall glycemia in the setting of pregnancy that is currently showing the most promise is GCD59. [35,36,37]

RISK FACTORS

1. A 25-year-old is deemed to be at low risk due to the age-related risk rise
2. Being overweight or obese
3. Family history
4. Having prediabetes
5. Having polycystic ovary syndrome
6. Being of a certain race or ethnicity, such as Black, Hispanic, American Indian and Asian American
7. Past history of pregnancy
    - women who have recently given birth to a huge child
    - Woman who have a history of GDM [38]

Complications that may affect your baby

1. Excessive birth weight.
2. Early (preterm) birth
3. Serious breathing difficulties
4. Low blood sugar (hypoglycemia)
5. Obesity
6. Type 2 diabetes later in life.
7. Stillbirth

Pathophysiology

Progressive insulin resistance, which starts during moderate pregnancy and continues through the third trimester, is a disorder specific to pregnancy. Insulin sensitivity decreases by about 50% in late pregnancy. Increased maternal obesity and the insulin-desensitizing effects of hormones generated by the placenta are two major factors that contribute to insulin resistance. The fact that post-delivery insulin resistance rapidly drops shows that placental hormones are the primary cause. Human chorionic somato-mammotrophs (HCS, formerly known as human placental lactogen), bound and free cortisol, estrogen, and progesterone are all produced by the placenta. In the fetus, HCS promotes pancreatic insulin secretion, but in the mother, it inhibits peripheral glucose uptake. The hormone production increases as the pregnancy goes on and the placenta grows larger, which causes the body to become more insulin-resistant. The first and second-phase insulin responses, which are connected to beta-cell hypertrophy and hyperplasia, make up for this decrease in insulin sensitivity in pregnant non-diabetic women. Women, however, who lack this extra insulin secretory potential, develop GDM. Women with GDM may have one of two major types of beta-cell dysfunction:

1. monogenic, or arising (as it most frequently does) against a backdrop of insulin resistance
2. Autoimmune [3]

MEDICAL NUTRITIONAL THERAPY (MNT)

Nutritional guidance should be provided to all GDM-afflicted women. For the needs of pregnancy, the food plan should supply enough calories and nutrients. [39] The cornerstone of treatment for women with GDM is MNT. In order to normalise blood glucose levels, the care of GDM specifically comprises calorie and nutrient restriction and modulation. The eating plan should ideally be created by a dietitian to meet the minimal nutritional needs for pregnancy and to achieve the desired glycemic levels without causing excessive weight gain or loss. Self-management treatment is called MNT. To help the women make the lifestyle adjustments necessary for effective nutrition therapy, education, support, and follow-up are needed. [40]

The following dietary guidelines have been recommended as suitable for someone with GDM in order to address the various needs: eating frequent, short meals of slowly digested carbohydrates to maintain blood glucose concentrations; (ii) consuming roughly the same amounts of carbohydrates each day at meals (particularly if the GDM is not treated with insulin); (iii) allowing a moderate amount of sugar-containing foods to be consumed as long as it does not result in hyperglycemia or excessive weight gain; (iv) consuming at least five portions of fruits and vegetables each day; (V) consuming meat, fish, poultry, and low-fat dairy meals; (VI) striving to eat two servings of oily fish each week; and (V) drinking a pint of milk or its equivalent each day. Additionally, the most recent revisions to the UK National Institute for Health and Clinical Excellence's recommendations for pregnant women with gestational diabetes mellitus (GDM) recommend that women with prepregnancy BMIs greater than 27 kg/m2 limit their daily calorie intake to 105kJ/kg or less and combine this with moderate exercise lasting at least 30 minutes per day. [41]

MANAGEMENT

In order to ensure a pregnant woman's and her unborn child's long-term health, gestational diabetes must be closely monitored and treated. The fifth international workshop conference on gestational diabetes recommended blood glucose levels of 90 to 99 mg/dL (5 to 5 mmol/L) for fasting, 7 to 8 mmol/L (140 mg/dL) for one hour after eating, and 6 to 7 to 1 mmol/L (120 to 127 mg/dL) for two hours after eating. [42]

GLUGOSE MONITORING

A pregnant woman with gestational diabetes can use self-glucose monitoring to check her blood glucose levels at any time and take action to reduce the long-term risks of diabetic problems for both her and her unborn child. Blood glucose metres come in a wide variety of designs, but they all function similarly and are generally accurate (although they are less accurate during episodes of hypoglycemia than during episodes of hyperglycemia).[43]

Less intrusive continuous glucose monitoring systems are currently being evaluated by researchers; their effectiveness has primarily been tested in type 1 diabetes patients. However, the use of technology for continuous glucose monitoring devices in the clinical care of gestational diabetes is growing. In 71 pregnant women with type 1 (n=46) or type 2 (n=25) diabetes who were either given prenatal care with continuous glucose monitoring (n=38) or conventional antenatal care (n=33), Murphy and colleagues investigated the effectiveness of continuous glucose monitoring devices. When compared to diabetic women who were randomly assigned to receive routine antenatal care, women who were randomly assigned to continuous glucose monitoring devices had lower mean glycosylated haemoglobin concentrations at 32–36 weeks' gestation (5.8% vs. 64%).In addition, the researchers found that when comparing the continuous glucose monitoring intervention group to the control group, there were lower mean birthweight SD scores (0.9 vs. 1.6), lower median customised birthweight centiles (69.9% vs. 93%), and lower odds of macrosomia (0.36 vs. 0-13-098). [44, 45]

Similar results were found by McLachlan and colleagues who examined 68 pregnant women with diabetes (including 37 with gestational diabetes, 10 with type 2 diabetes, and 8 with type 1 diabetes) and evaluated the effectiveness of continuous glucose monitoring systems. These researchers also shown that, in over two-thirds (62%) of cases, data from continuous glucose monitoring devices led to changes in clinical management decisions, with an indication of undiagnosed and potentially deadly postprandial hyperglycaemia and nocturnal hypoglycaemia. [46]

NUTRITION AND DIET

The first line of management for women with gestational diabetes is medical nutrition therapy together with supplementary activity for at least 30 minutes each day, in addition to blood glucose monitoring. Insulin injections or other antihyperglycemia drugs are given to patients who are unable to achieve their glycaemic objectives through diet and exercise therapy.

Although a growing body of research indicates that nutritional support during pregnancy may have a significant impact on the prevalence and severity of gestational diabetes, the management of this condition through nutrition is contentious. [46]

In a 2003 Cochrane analysis, women with gestational diabetes who were randomly assigned to primary dietary therapy or no specific treatment showed no difference in the prevalence of birthweights more than 4000 g or caesarean births. The authors came to the conclusion that there is insufficient data to suggest nutritional therapy for people with impaired glucose metabolism. However, the American Diabetes Association (ADA) advises that pregnant women with gestational diabetes undergo nutrition guidance and adhere to a diet that sufficiently covers their needs while limiting their intake of carbs to 35–40% of daily calories. This advice is supported by studies that shows better maternal and foetal outcomes can be achieved by limiting carbohydrates to 35–40% of total calories.Additionally, studies have demonstrated that limiting carbohydrates to 30–33% of daily calories (or roughly 25 kcal/kg real weight per day) may be advantageous for obese women with BMIs greater than 30. [47]

EXERCISE

Exercise during pregnancy can reduce difficulties for the unborn child, according to research. Prenatal exercise has been proven to delay or prevent the development of gestational diabetes. To determine if the quantity, kind, and intensity of prenatal physical activity and sedentary behaviors are related to the risk of developing gestational diabetes, Zhang and colleagues conducted a prospective cohort research in over 22 000 women. In comparison to women who watched less television and engaged in physical exercise, those who watched 20 hours or more of television per week or more had a higher risk of acquiring the illness. Regular exercisers with gestational diabetes had a lower risk of giving birth to large-for-gestational-age children than non-exercisers. [48,49]

PHARMACOLOGICAL TRETMENT

When diet and exercise fail, as shown by an anomaly in more than half of self-monitored glucose readings or an abnormal value in women who are tested weekly, pharmacologic therapy is most frequently started. Numerous studies also found that pharmaceutical therapies had better results for women who did not achieve their goals with diet and exercise alone. Some women's GDM cannot be adequately controlled by diet and exercise alone, particularly those with a rather severe type of the disorder that appears earlier than in the third

trimester. In these situations, pharmacological treatment is necessary to lower circulating maternal glucose concentrations and the danger of increased foetal growth that goes along with it, as well as to prevent any harmful (for example, teratogenic) effects on the foetus if the medication being used for treatment crosses the placenta. Therefore, the following are the main pharmaceutical therapies employed in the therapy of GDM. [2,50]

INSULIN THERAPY

Pharmacotherapy with insulin is advised when individuals are unable to regulate their blood sugar levels by diet and exercise. A fasting blood sugar level of 95 mg/dL or more is a prerequisite for starting pharmacologic treatment, as are postprandial blood sugar levels of 120 mg/dl for two hours or 140 mg/dl for an hour. Insulin therapy is the gold standard when it comes to GDM treatments because it is secure and efficient. The short-acting insulin analogues lispro (Humalog) and Aspart (Novolog), as well as regular and NPH insulin, are regarded as safe for use. [51]

Our own insulin production can be "topped up" with an insulin injection at mealtime if blood glucose levels are climbing outside of the intended range. Insulin may be required at some or all of our meals. Sometimes we may need to "top up" the insulin that was created between meals and overnight. The extra slower-acting insulin may be needed at sleep as a result. The diabetic experts will inform us when and how much insulin we need to take.[52]

Women with GDM who need insulin treatment can receive it without a hospital stay. The insulin dosage is based on the weight of the mother. Insulin is dosed in one insulin regimen at 0.7 units/kg of real body weight. This dosage is lower than for diabetic patients who do not have GDM. The goal of this more cautious form of treatment is to stop hypoglycemia. Two-thirds of the doses are given before breakfast (one-third regular insulin and one-third NPH insulin), making up the entire daily dose; the remaining one-third is divided into two doses (one-half regular insulin before supper and one-half NPH insulin before night).[51]

A subcutaneous applicator of exogenous insulin should have similar pharmacologic characteristics to insulin released from the pancreas in healthy individuals in order to attain the near-normal glycemia. More attempts have been made to modify the insulin molecule in an effort to improve its pharmacokinetic characteristics. Changes in the tertiary structure can be made by altering the primary amino acid sequence, and these changes may have an impact on how molecules associate and how long insulin receptors remain bound. These alterations may also boost the mitogenic effects of analogues. Compared to conventional human insulin, the insulin lispro can better control postprandial hyperglycemia without raising the risk of hypoglycemia. Clinical investigations have shown that giving insulin right before a meal reduces postprandial hyperglycemia and the number of nocturnal hypoglycemia episodes more effectively than giving normal insulin 30 minutes beforehand.

On the usage of glargine during pregnancy, there is only one report. The type 1 patient was given glargine instead of NPH because she frequently experienced severe nighttime hypoglycemia episodes. The patient had never before experienced retinopathy, and pregnancy does not cause it. Women with gestational diabetes who receive insulin treatment see a decrease in surgical deliveries and birth trauma, according to a prospective nonrandomized trial involving 445 participants. The conclusion of this study still has to be supported by an RCT with sufficient power, though.

There are no specific studies claiming that a certain regimen or kind of insulin is preferable in terms of influencing any perinatal outcomes. A typical first dosage is 0.7 units per kg per day, divided into two doses of one-third of the entire quantity given in the morning and one-third in the evening. Each dose contains one-third conventional insulin and the other two thirds NPH insulin. The safety of very short-acting insulin lispro, which can be taken with once-daily prolonged insulin ultra-lente, is supported by a recent study of 42 pregnant women with gestational diabetes. The best method for controlling blood glucose level is the simplest one. [53]

ORAL HYPOGLYCEMIC AGENTS

1. METFORMIN

For the treatment of diabetes outside of pregnancy, metformin is a pill that has been used successfully for approximately 40 years. It is being used more frequently during pregnancy as a complement to or a substitute for insulin. [52]

Metformin reduces the physiological increase in insulin resistance that occurs during pregnancy, which would be predicted to improve tolerance in pregnancy as it increases insulin sensitivity. For patients with polycystic ovarian syndrome (PCOS), the biguanide metformin during pregnancy has primarily been examined in the first 12 weeks of pregnancy. In women with PCOS, preliminary research suggests that metformin treatment throughout pregnancy may be safe and may lower the risk of miscarriage and the emergence of GDM. Metformin may also be used to treat GDM; a multicenter trial is now being conducted in New Zealand to investigate this possibility. [54]

A smaller dose of insulin will function better thanks to the way that metformin makes it possible for insulin to perform more efficiently. This may imply that your own meagre insulin production, along with metformin to enhance its activity, may be sufficient to control blood glucose levels. In addition to insulin shots, metformin can be helpful. Combining these can help maintain insulin dosages low. Pregnancy outcomes can be improved by preventing excessive weight gain during pregnancy. Metformin does traverse the placenta, unlike insulin. Your diabetes doctor in the clinic will be pleased to talk with you about the various studies that have looked at the safety of metformin during pregnancy. Not everyone is a candidate for metformin.

Additionally, some medical issues or complications associated with pregnancy may indicate that insulin might be a preferable option. When using metformin, some people (2 out of every 10) may develop unwanted effects, such as stomach discomfort. These can be reduced by beginning with a low dose, increasing the dose gradually, and taking the tablet with or right after eating. [52]

2. GLYBURIDE

In the recent years, this sulfonylurea has been discovered as an alternative to insulin therapy for the treatment of GDM. Enhancing insulin secretion is its main effect. Glyburide seldom crosses the placenta at all. Glyburide has been proven to be an effective substitute for insulin for the treatment of GDM with effects for the foetus that are comparable. According to a survey by the American colleges of obstetricians and gynaecologists, 13% of obstetricians and maternal-fetal medicine specialists treat women with GDM who are unable to regulate their blood sugar levels with diet alone. Glyburide has the drawback that sometimes it takes more than one week to see the effects of titration. It has been discovered to be just as effective as insulin therapy for the treatment of GDM, although being less expensive and invasive than insulin. [3]

Glyburide is a pregnancy category C drug. Glyburide is a sulfonylurea, which means that hypoglycemia can happen with any of them. With glyburide, hypoglycemia can occur anywhere between 1 and 5% of the time. The most frequent side effects are dermatologic (pruritis, urticaria, erythema, and maculopapular eruptions) and gastrointestinal (nausea, vomiting, dyspepsia). Jaundice is uncommon, however elevated liver function tests have been noted. From 3.2 to 4.1% of unfavourable effects occur on average.

When choosing medicinal therapy for the treatment of gestational diabetes, it is crucial to identify those women who might fail glyburide medication in pregnancy. Conway discovered that among women with high FPG levels more than or equal to 110 mg/dl, 24% did not react to glyburide medication in an observational trial to look at characteristics predicting failure of glyburide treatment in gestational diabetes. Glyburide's ability to enter a breastfeeding mother's milk has been the subject of studies. There were no reports of neonatal hypoglycemia, and it seems safe for mothers using glyburide to breastfeed. But no decision-making body has approved the medication for regular usage in GDM. [55]

3. ACARBOSE

The effectiveness of acarbose in treating diabetic pregnant women has not been thoroughly studied. Acarbose was used to control the blood sugar levels of six women in a report from Mexico. The pregnancies were complicated by the healthy baby deliveries. The increased amount of starch in the bowels of the women treated with acarbose may be the cause of the potential adverse (albeit unproven) effect of acarbose on pregnancy. The bacterial breakdown of starch results in the buildup of butyrate, which could enhance the release of prostaglandin E and have harmful effects on pregnancy.

Two preliminary investigations suggest that acarbose is effective in lowering postprandial glucose excursions in GDM, albeit with the expected high frequency of cramps since it is poorly absorbed from the gastrointestinal system. Safety and potential transplacental transit have not been thoroughly assessed, and only a small percentage of this medication may be absorbed systemically.[55]

CONCLUSION

In order to effectively manage gestational diabetes, the clinical state of each individual case must be determined over time. Obstetricians, gynaecologists, nutritionists, paediatricians, cardiovascular nephrologists, ophthalmologists, and nursing staff provide multidisciplinary management and treatment in addition to the cooperation of family members.

Obstetricians and endocrinologists continue to face challenges in providing GDM with the best possible care. The most popular treatment for GDM, MNT, is sufficient when used as directed. When pharmacological treatment is required, human insulin is the drug of choice. Regular human insulin may be replaced by fast-acting insulin analogues. Due to the lack of available data, long-acting analogues are not currently advised for use during pregnancy. In GDM, the transition from insulin to OHAs has been fantastic. OHAs are now seated at the highest levels of GDM management. Both glyburide and metformin have been proven to be affordable, safe, and efficient treatments for gestational diabetes

They have also been confirmed to be safe for breastfed babies. Before they can be suggested as first-line treatments for pre-gestational and gestational diabetes, more research is required to determine the risks and advantages of these and other oral hypoglycemic medications. They can, however, be utilised when insulin delivery is either impractical or the patient does not tolerate it.

Obstetricians and endocrinologists must work together to provide GDM patients with the best care possible, but a proactive clinician is most important. Let's work together to efficiently manage the GDM for both the current generation and future generations.

REFERENCES

1 Sanders of medical care in diabetes, American diabetes association, care diabetes journal org; 2013.

2 Clive J, Petry. Gestational diabetes: risk factors and recent advances in its genetics and treatment. Br J Nutr 2010;104:775-87.

3 Jennifer M, Perkins MD, Julia P, Dunn MD, Shubhada M, Jagasia MD. Perspectives in gestational diabetes mellitus: a review of screening, diagnosis, and treatment. Clin Diabetes Res 2001;25:57-62.

4 Takashi Sugiyama. Management of gestational diabetes mellitus. JMAJ 2011;54:293-300.

5 WHO Guidelines Approved by the Guidelines Review Committee. Diagnostic Criteria and Classification of Hyperglycaemia First Detected in Pregnancy. Geneva: World Health Organization; 2013

6 Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med. 2005;352:2477–2486

7 International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, Dyer AR, Leiva Ad, Hod M, Kitzmiler JL, Lowe LP, McIntyre HD, Oats JJ, Omori Y, Schmidt MI. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:676–682.

8 Sacks DA, Metzger BE. Classification of diabetes in pregnancy: time to reassess the alphabet. Obstet Gynecol. 2013;121:345–348.

9 ACOG technical bulletin. Diabetes and pregnancy. Number 200-December 1994 (replaces No. 92, May 1986). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1995;48:331–339.

10 Chamberlain C, McNamara B, Williams ED, Yore D, Oldenburg B, Oats J, Eades S. Diabetes in pregnancy among indigenous women in Australia, Canada, New Zealand and the United States. Diabetes Metab Res Rev. 2013;29:241–256.

11 HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, Hadden DR, McCance DR, Hod M, McIntyre HD, Oats JJ, Persson B, Rogers MS, Sacks DA. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.

12 Landon MB, Spong CY, Thom E, Carpenter MW, Ramin SM, Casey B, Wapner RJ, Varner MW, Rouse DJ, Thorp JM Jr, Sciscione A, Catalano P, Harper M, Saade G, Lain KY, Sorokin Y, Peaceman AM, Tolosa JE, Anderson GB; Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. A multicenter, randomized trial of treatment for mild gestational diabetes. N Engl J Med. 2009;361:1339–1348.

13 Sedgh G, Singh S, Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. Stud Fam Plann (2014) 45:301–14. doi: 10.1111/j.1728-4465.2014.00393.x

14 Seshiah V, Balaji V, Balaji MS, Panneerselvam A, Thamizharasi M, Arthi T. Glycemic level at the first visit and prediction of GDM. J Assoc Physicians India (2007) 55:630–2.

15 Lorenzo-Almoros A, Hang T, PeiroC, Soriano-Guillen L, Egido J, TuñonJ, et al. Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases. Cardiovasc Diabetol (2019) 18:140. doi: 10.1186/s12933-019-0935-9

16 Powe CE. Early Pregnancy Biochemical Predictors of Gestational Diabetes Mellitus. Curr Diabetes Rep (2017) 17:12. doi: 10.1007/s11892-017-0834-y

17 Artzi NS, Shilo S, Hadar E, Rossman H, Barbash-Hazan S, Ben-Haroush A, et al. Prediction of gestational diabetes based on nationwide electronic health records. Nat Med (2020) 26:71–6. doi: 10.1038/s41591-019-0724-8

18 Sweeting AN, Wong J, Appelblom H, Ross GP, Kouru H, Williams PF, et al. A f irst trimester prediction model for gestational diabetes utilizing aneuploidy and pre-eclampsia screening markers. J Matern Fetal Neonatal Med (2018) 31:2122–30. doi: 10.1080/14767058.2017.1336759

19 Yoffe L, Polsky A, Gilam A, Raff C, Malacca F, Ognibene A, et al. Early diagnosis of gestational diabetes mellitus using circulating microRNAs. Eur J Endocrinol (2019) 181:565–77. doi: 10.1530/EJE-19-0206

20 Abdeltawab A, Zaki ME, Abdeldayem Y, Mohamed AA, Zaied SM. Circulating micro RNA-223 and angiopoietin-like protein 8 as biomarkers of gestational diabetes mellitus. Br J BioMed Sci (2020) 1–6. doi: 10.1080/ 09674845.2020.1764211

21 Filardi T, Catanzaro G, Mardente S, Zicari A, Santangelo C, Lenzi A, et al. Non-Coding RNA: Role in Gestational Diabetes Pathophysiology and Complications. Int J Mol Sci (2020) 21:4020. doi: 10.3390/ijms21114020

22 Herrera-Van Oostdam AS, Salgado-Bustamante M, Lopez JA, Herrera-Van Oostdam DA, Lopez-Hernandez Y. Placental exosomes viewed from an 'omics' perspective: implications for gestational diabetes biomarkers identification. Biomark Med (2019) 13:675–84. doi: 10.2217/bmm-2018-0468

23 James-Allan LB, Rosario FJ, Barner K, Lai A, Guanzon D, McIntyre HD, et al. Regulation of glucose homeostasis by small extracellular vesicles in normal pregnancy and in gestational diabetes. FASEB J (2020) 34:5724–39. doi: 10.1096/fj.201902522RR

24 Cheung KW, Wrong SF. Gestational diabetes mellitus update and review of the literature. Reproductive Sys Sexual Disord 2011;S:2.

25 Colagiuri S, Falavigna M, Agarwal MM, Boulvain M, Coetzee E, Hod M, et al. Strategies for implementing the WHO diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Diabetes Res Clin Pract (2014) 103:364–72. doi: 10.1016/j.diabres.2014.02.012

26 HodM,KapurA,SacksDA,HadarE,AgarwalM,DiRenzoGC,etal.TheInternational Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes mellitus: A pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet (2015) 131 Suppl 3:S173–211. doi: 10.1016/S0020-7292(15)30033-3

27 Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care (2010) 33:676–82. doi: 10.2337/dc10-0719

28 A.C.o.P. Bulletins. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol (2018) 131:e49–64. doi: 10.1097/AOG. 0000000000002501

29 Meththananda Herath HM, Weerarathna TP, Weerasinghe NP. Is Risk Factor-based Screening Good Enough to Detect Gestational Diabetes Mellitus in High-Risk Pregnant Women? A Sri Lankan Experience. Int J Prev Med (2016) 7:99. doi: 10.4103/2008-7802.188084

30 Bonongwe P, Lindow SW, Coetzee EJ. Reproducibility of a 75G oral glucose tolerance test in pregnant women. J Perinatal Med (2015) 43:333–8. doi: 10.1515/jpm-2014-0208

31 Dunseath GJ, Bright D, Jones C, Dowrick S, Cheung WY, Luzio SD. Performance evaluation of a self-administered home oral glucose tolerance test kit in a controlled clinical research setting. Diabetes Med (2019) 36:862–7. doi: 10.1111/dme.13961

32 Dhatt GS, Agarwal MM,OthmanY,NairSC.PerformanceoftheRocheAccuChek active glucose meter to screen for gestational diabetes mellitus using fasting capillary blood. Diabetes Technol Ther (2011) 13:1229–33.

33 Lowe LP, Metzger BE, Dyer AR, Lowe J, McCance DR, Lappin TR, et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care (2012) 35:574–80.

34 Hughes RC, Moore MP, Gullam JE, Mohamed K, Rowan J. An early pregnancy HbA1c >/=5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care (2014) 37:2953–9.

35 Mendes N, Tavares Ribeiro R, Serrano F. Beyond self-monitored plasma glucose and HbA1c: the role of non-traditional glycaemic markers in gestational diabetes mellitus. J Obstet Gynaecol (2018) 38:762–9

36 Ghosh P, Luque-Fernandez MA, Vaidya A, Ma D, Sahoo R, Chorev M, et al. Plasma Glycated CD59, a Novel Biomarker for Detection of PregnancyInduced Glucose Intolerance. Diabetes Care (2017) 40:981–4.

37 Bogdanet D, O'Shea PM, Halperin J, Dunne F. Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM)- protocol for prospective cohort study. BMC Pregnancy Childbirth (2020) 20:412. doi: 10.1186/s12884-02003090-9

38 Howard Berger MD, Joan Crane MD, Dan Farine MD. Screening for gestational diabetes mellitus. SOGC clinical practice guidelines; 2002. p. 121.

39 Balaji V, Seshiah V. Management of diabetes in pregnancy. JAPI 2011;59:108-12.

40 Navneet Magon, V Seshiah. Gestational diabetes mellitus: noninsulin management. Indian J Endocrinol Metab 2011;15:284-93.

41 National Institute for Health and Clinical Excellence, diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. Available from:http://www.nice.org.uk/nicemedia/pdf/DiabetesFullGuideline RevisedJULY2008.pdf. [Last accessed on 20 Aug 2016]

42 Metzger BE, Buchanan TA, Coustan DR, et al. Summary and recommendations of the Fifth International WorkshopConference on Gestational Diabetes Mellitus. Diabetes Care 2007; 30: S251–60.

43 Murata GH, Duckworth WC, Shah JH, Wendel CS, Hoff man RM. Factors aff ecting hypoglycemia awareness in insulin-treated type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Diabetes Res Clin Pract 2004; 65: 61–67.

44 JDRF CGM Study Group. JDRF randomized clinical trial to assess the effi cacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods. Diabetes Technol Ther 2008; 10: 310–21.

45 Murphy HR, Rayman G, Lewis K, et al. Eff ectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ 2008; 337: a1680.

46 Major CA, Henry MJ, De Veciana M, Morgan MA. The eff ects of carbohydrate restriction in patients with diet-controlled gestational diabetes. Obstet Gynecol 1998; 91: 600–04.

47 Franz MJ, Horton ES, Bantle JP, et al. Nutrition principles for the management of diabetes and related complications (Technical Review). Diabetes Care 1994; 17: 490–518.

48 Zhang C, Solomon CG, Manson JE, Hu FB. A prospective study of pregravid physical activity and sedentary behaviors in relation to the risk for gestational diabetes mellitus. Arch Intern Med 2006; 166: 543–48.

49 Snapp CA, Donaldson SK. Gestational diabetes mellitus: physical exercise and health outcomes. Biol Res Nurs 2008; 10: 145–55.

50 Gabriella P, Tara D Benjamin. Update on gestational diabetes. Obstet Gynecol Clin N Am 2010;37:255-67.

51 Karen von Koeckritz. Current management of Gestational Diabetes Mellitus. Von Koeckritz-Gestational Diabetes; 2014. p. 1-7.

52 Gestational Diabetes–Medication Treatment Options. Patient Information, Cambridge University Hospitals. NHS; 2016. p. 1-3.

53 David KT, Stephen DR, Elizabeth GB. Management of gestational diabetes mellitus . Am Fam physician 2003;68:1767-72, 1775-6.

54 Steve LH, Jyoti B, Antoinette J, Hassan S. Metformin treatment for gestational diabetes. Br J Diabetes Vasc Dis 2009;9:220-5.

55 Navneet Magon, V Seshiah. Gestational diabetes mellitus: noninsulin management. Indian J Endocrinol Metab 2011;15:284-93.